Skip to main content
SHIELD THERAPEUTICS PLC logo

SHIELD THERAPEUTICS PLC — Investor Relations & Filings

Ticker · STX ISIN · GB00BYV81293 LEI · 213800G74QWY15FC3W71 IL Manufacturing
Open in API
Filings indexed 408 across all filing types
Latest filing 2019-04-01 Regulatory Filings
Country GB United Kingdom
Listing IL STX

About SHIELD THERAPEUTICS PLC

https://www.shieldtherapeutics.com/

Shield Therapeutics is a commercial-stage specialty pharmaceutical company focused on addressing iron deficiency. The company's mission is to improve the lives of patients suffering from this condition, with or without anemia. Its lead product is Accrufer® (ferric maltol), also marketed as Feraccru®, a novel, stable, non-salt-based oral therapy. This innovative pharmaceutical is broadly indicated for use in adults across multiple therapeutic categories, aiming to provide an effective and well-tolerated treatment for a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Change of Adviser
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and is dated 01 April 2019. The content announces a 'Change of Adviser' (appointment of Peel Hunt LLP as Nominated Adviser) and provides contact details for various advisors. The closing section explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.' This structure and explicit mention of RNS strongly indicate a general regulatory announcement made via the London Stock Exchange's Regulatory News Service. Since the announcement is about an administrative change (adviser change) and not a specific financial report (like 10-K, ER, or IR), the most appropriate classification is the general regulatory filing category, RNS.
2019-04-01 English
Positive decision on Feraccru®'s process patent
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated March 14, 2019. The content announces a specific legal/intellectual property event: the European Patent Office (EPO) reaching a positive decision regarding a process patent for their product Feraccru®. This type of announcement, which details a specific, material event concerning intellectual property or regulatory status outside of standard financial reporting periods (like earnings or annual reports), is typically disseminated via regulatory news services. The presence of the RNS header and the nature of the announcement strongly suggest it is a general regulatory filing or news release. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it is a specific, material announcement, the most appropriate category is Regulatory Filings (RNS), which serves as the general category for such news releases distributed through official channels like the London Stock Exchange's RNS system.
2019-03-14 English
Positive results for Feraccru® in AEGIS-H2H study
Earnings Release Classification · 99% confidence The document begins with an 'RNS Number' and the date '04 March 2019', indicating it is a regulatory announcement disseminated via the London Stock Exchange's RNS service. The content details positive clinical trial results for a drug (Feraccru®), mentions an associated milestone payment, and includes standard boilerplate information about the company, its product, and forward-looking statements, concluding with the RNS distribution notice. This structure is characteristic of a general regulatory news service announcement rather than a comprehensive statutory report (like 10-K or IR) or a specific financial event document (like DIV or CAP). Since it is a general regulatory announcement that doesn't fit the more specific categories (like DIRS, MANG, or ER), the most appropriate classification is the general regulatory filing category. FY 2018
2019-03-04 English
Positive results of AEGIS-CKD study
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated January 29, 2019. It contains a headline announcing positive results from a clinical study ('Positive results of long-term phase of AEGIS-CKD study...') and provides key financial/clinical highlights, followed by quotes from management. The document concludes with contact information and a standard disclaimer referencing RNS and the London Stock Exchange. This structure is characteristic of a press release announcing significant company news, specifically clinical trial results, which falls under the category of a general regulatory announcement or news service release. Since it is a news announcement and not a comprehensive periodic report (like 10-K or IR), and it is explicitly distributed via RNS, the most appropriate classification is Regulatory Filings (RNS), as it serves as the general regulatory announcement channel.
2019-01-29 English
Hardman & Co Research: Shield Therapeutics (STX): Cast-iron investment
Regulatory Filings Classification · 99% confidence The document is a short announcement (3777 characters) from 'Hardman & Co Research' regarding Shield Therapeutics. It provides a brief summary of the company and its prospects, but crucially, it explicitly states: 'Please click here for the full report:' followed by a hyperlink. This structure—a brief notice pointing to a longer, attached or linked document—fits the definition of a Report Publication Announcement (RPA) according to Rule #2 (The 'MENU VS MEAL' Rule). It is not the full research report itself, but the announcement of its availability.
2019-01-28 English
Business and trading update
Earnings Release Classification · 99% confidence The document begins with an 'RNS Number' and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' The content is a 'Business and trading update' for the year ended 31 December 2018, providing unaudited financial highlights and operational updates. This format—a brief, timely announcement of key operational and financial performance metrics, often released outside of the main annual or quarterly report cycle—is characteristic of an Earnings Release (ER) or a general regulatory announcement. Since it provides key financial highlights (Revenues, Cash position) for a period, ER is a strong candidate. However, because it is explicitly distributed via RNS and serves as a general market update rather than a formal, comprehensive quarterly report (IR) or annual report (10-K), and given the presence of the RNS header, it fits well under the general regulatory announcement category, RNS, or the specific Earnings Release (ER) category. Given the inclusion of specific financial highlights for a period ('year ended 31 December 2018'), ER is more precise than the general RNS fallback. The document is not a full report, but an update/release. FY 2018
2019-01-24 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.